Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Monte Rosa Therapeutics Q3 EPS $(0.33) Beats $(0.37) Estimate, Sales $12.768M Beat $5.420M Estimate

Author: Benzinga Newsdesk | November 06, 2025 08:01am
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.37) by 11.53 percent. This is a 13.79 percent decrease over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $12.768 million which beat the analyst consensus estimate of $5.420 million by 135.57 percent. This is a 38.54 percent increase over sales of $9.216 million the same period last year.

Posted In: GLUE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist